Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.44 |
| ▸ | AXL | P30530 | 5/20 | 0.44 |
| ▸ | KDR | P35968 | 4/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | EIF2AK3 | Q9NZJ5 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29684215 | 1.00 | MET (0.44) | METAXLKDRIMPDH2FLT3 | |
| SCHEMBL23043903 | 0.86 | FLT3 (0.50) | METAXLFLT3EGFRCDK1 | |
| SCHEMBL29684025 | 0.85 | FLT3 (0.55) | METAXLKDRFLT3EGFR | |
| SCHEMBL23043916 | 0.85 | FLT3 (0.55) | METAXLKDRFLT3EGFR | |
| SCHEMBL29746670 | 0.85 | MET (0.49) | METAXLFLT3EGFRCDK1 | |
| SCHEMBL23043850 | 0.85 | MET (0.49) | METAXLFLT3EGFRCDK1 | |
| SCHEMBL29746539 | 0.82 | EIF2AK3 (0.51) | METAXLKDRFLT3EGFR | |
| SCHEMBL23057572 | 0.82 | FLT3 (0.44) | METAXLFLT3EGFRCDK1 | |
| SCHEMBL23044049 | 0.82 | EIF2AK3 (0.51) | METAXLKDRFLT3EGFR | |
| SCHEMBL29746667 | 0.82 | FLT3 (0.44) | METAXLFLT3EGFRCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356186-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | HIBERCELL, INC. | 2022-11-10 | — | — | US | claimed |
| EP-4021908-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | Hibercell, Inc. (US) | 2022-07-06 | — | — | EP | claimed |
| CN-114710956-A | PERK-INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | 希伯塞尔股份有限公司 | 2022-07-05 | — | — | CN | claimed |
| WO-2021231788-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS TO TREAT VIRAL INFECTIONS | HIBERCELL, INC. (US) | 2021-11-18 | — | — | WO | claimed |
| WO-2021041975-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | claimed |
| US-20220356186-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | HIBERCELL, INC. | 2022-11-10 | — | — | US | disclosed |
| EP-4021908-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | Hibercell, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114710956-A | PERK-INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | 希伯塞尔股份有限公司 | 2022-07-05 | — | — | CN | disclosed |
| WO-2021231788-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS TO TREAT VIRAL INFECTIONS | HIBERCELL, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021041975-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021041975-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356186-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | EEF2K, ATF4, MAPKAPK2 | MET 839/4885AXL 3904/4885KDR 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.